Frequency and molecular characteristics of PALB2‐associated cancers in Russian patients

PALB2 is а high‐penetrance gene for hereditary breast cancer (BC). Our study aimed to investigate the spectrum of PALB2 mutations in Russian cancer patients. PALB2 sequencing revealed pathogenic variants in 3/190 (1.6%) young‐onset and/or familial and/or bilateral BC cases but none in 96 ovarian cancer (OC) or 172 pancreatic cancer patients. Subsequently, seven recurrent PALB2 pathogenic alleles were selected from this and previous Slavic studies and tested in an extended patient series. PALB2 pathogenic variants were detected in 5/585 (0.9%) “high‐risk” BC, 10/1508 (0.7%) consecutive BC and 5/1802 (0.3%) OC cases. Haplotyping suggested that subjects with Slavic alleles c.509‐510delGA (n = 10) and c.172‐175delTTGT (n = 4) as well as carriers of Finnish c.1592delT mutation (n = 4) originated from a single founder each, while PALB2 p.R414X allele (n = 4) had at least two independent founders. Somatic loss of heterozygosity (LOH) was revealed in 5/10 chemonaive BCs and in 0/2 BC samples obtained after neoadjuvant therapy. Multigene sequencing identified somatic PALB2 inactivating point mutation in one out of two tumors without PALB2 LOH but in none of four BCs with PALB2 LOH. Genomic instability, as determined by NGS, was observed in four out of five tumors with biallelic PALB2 inactivation but not in the BC sample with the preserved wild‐type PALB2 allele. PALB2 germ‐line mutations contribute to a small fraction of cancer cases in Russia. The majority although not all PALB2‐driven BCs have somatic inactivation of the remaining PALB2 allele and therefore potential sensitivity to platinum compounds and PARP inhibitors. What's new? Variations in the PALB2 gene are associated with increased risk of hereditary breast cancer. The effect of PALB2 germ‐line mutations on cancer predisposition, however, remains unknown. Here, in a Russian cohort, about 1 percent of high‐risk breast cancer patients carried PALB2 pathogenic variants, with a lower frequency of variants identified in consecutive breast cancer cases. Ovarian cancer risk was marginally elevated in PALB2 mutation carriers. In addition, while several recurrent PALB2 alleles originated from a single founder, p.R414X had at least two independent ancestors, suggesting a possible mutation hotspot. Somatic inactivation of the remaining PALB2 allele may affect therapeutic response.